Status:

COMPLETED

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

Lead Sponsor:

Cadence Pharmaceuticals

Conditions:

Infection

Eligibility:

All Genders

13+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether treatment with topical omiganan is more effective than treatment with topical povidone-iodine in preventing local catheter site infections and cathete...

Detailed Description

Study design: This is a phase 3, multi-center, randomized, Evaluation Committee-blinded study in patients undergoing noncuffed central venous catheterization using either a single lumen or multi-lume...

Eligibility Criteria

Inclusion

  • New insertion of at least 1 noncuffed (nontunneled) temporary central venous catheter
  • Males and females of at least 13 years of age
  • A negative urine or serum pregnancy test at baseline

Exclusion

  • Insertion of, or requirement for, any study catheter impregnated/bonded with an antimicrobial substance
  • High probability of death within 14 days of enrollment as assessed by the investigator
  • Prior treatment with vancomycin (intravenous administration only), daptomycin, linezolid, or quinupristin/dalfopristin, within 48 hours of first study catheter insertion or prior treatment with tigecycline within one week of first study catheter insertion
  • Requirement for topical antibiotic use within 10 cm of any study catheterization site
  • Known severe neutropenia (absolute neutrophil count \[ANC\] \< 500 mm3) or recent administration of antineoplastic therapy expected to result in severe neutropenia within 48 hours of first study catheter insertion
  • Routine non-complicated coronary artery bypass grafting (CABG) patients, bone marrow transplant (BMT) or solid organ transplant (SOT) patients
  • Patients anticipated to be catheterized for less than 48 hours
  • Patients who have a suspected or known bloodstream infection at enrollment
  • Burn patients or patients with toxic epidermal necrolysis
  • Known allergy to adhesive tape or adhesive bandages

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2008

Estimated Enrollment :

1859 Patients enrolled

Trial Details

Trial ID

NCT00231153

Start Date

August 1 2005

End Date

July 1 2008

Last Update

August 13 2009

Active Locations (57)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (57 locations)

1

Mobile, Alabama, United States

2

Phoenix, Arizona, United States

3

Arcadia, California, United States

4

Glendale, California, United States